Jasper Therapeutics (JSPR) vs Pluri (PLUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pluri (PLUR) has outperformed Jasper Therapeutics (JSPR) over the past year, losing 75.5% versus a loss of 76.7%. Over five years, PLUR leads with a -95.2% price change compared with -99.7% for JSPR. Jasper Therapeutics is the larger company by market cap ($19.0 million vs $12.6 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JSPR | PLUR |
|---|---|---|
| Share price | $0.5709 | $1.00 |
| Market cap | $19.00M | $12.61M |
| 1-day change | +1.95% | 0.00% |
| YTD return | -69.40% | -66.56% |
| 1-year return | -76.67% | -75.49% |
| 5-year return | -99.66% | -95.23% |
| EPS (TTM) | $-1.04 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.69 | $4.87 |
| 52-week low | $0.315 | $0.85 |
| Distance from 52-week high | -78.78% | -79.47% |
| Analyst consensus | none | — |
| Avg. price target upside | +3403.24% | — |
| Average volume | 1.37M | 24.97K |
| Shares outstanding | 33.27M | 12.61M |
| Employees | — | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Jasper Therapeutics
JSPR stock →Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About Pluri
PLUR stock →Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees
JSPR vs PLUR FAQ
Which is bigger, Jasper Therapeutics or Pluri?
Jasper Therapeutics (JSPR) is larger, with a market capitalization of $19.00M compared with $12.61M for Pluri (PLUR).
Which stock has performed better over the past year, JSPR or PLUR?
PLUR returned -75.49% over the past 12 months, compared with -76.67% for JSPR (price return, excluding dividends). Past performance does not predict future results.
Are Jasper Therapeutics and Pluri in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.